Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Guided Therapeutics (GTHP) Asset Writedowns and Impairment (2016 - 2025)

Guided Therapeutics' Asset Writedowns and Impairment history spans 6 years, with the latest figure at $3000.0 for Q4 2025.

On a quarterly basis, Asset Writedowns and Impairment rose 400.0% to $3000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4000.0, a 300.0% increase, with the full-year FY2025 number at $6000.0, changed N/A from a year prior.
Asset Writedowns and Impairment hit $3000.0 in Q4 2025 for Guided Therapeutics, up from $2000.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for GTHP hit a ceiling of $3000.0 in Q4 2025 and a floor of -$1000.0 in Q4 2024.